Crossing Boundaries The Do's and Don'ts of a Med School Professor Starting a Business • Traditional Academic World – Goal: Understand and Communicate Something That Other People Can Learn – Propose and Prove Hypotheses; Publications (Scientists) – Inventions seem to appear “out of the blue” in this setting • The Corporate World – Goal: Make Something That Other People Can Use – Deliverables and Applications Oriented; Products (Entrepreneurs) – Innovations occur by collaboration and networking in this setting • The New Translational Science – Teach and Encourage Innovation – Promote an Entrepreneurial Spirit Invention (Patent) Innovator Steve Jobs “Stay hungry. Stay foolish.” Innovation Henry Ford was an Innovator Antigen Discovery Inc. Antigen Discovery Xiaowu Liang Angela Yee Doug Molina Gary Hemanson Andy Teng Vu Huynh Scott Weiss Jiin Felgner Pierre Baldi, UCI Matt Kayala Michael Zeller Arlo Randall Abe Lee, UCI Armando Tovar Arlene Doria Maulik Patel Peter Crompton, NIAID Joe Vinetz, UCSD Denise Doolan, QIMR Angela Trieu Robert Sauerwein, Nijmegen Rob Hermsen Carlota Dobano, Barcelona Joe Campo P. falciparum protein microarray containing 4,528 proteins USA Malaria Naïve Adult Naturally Exposed Resident of Mali West Africa Inventory of Cloned Genes, Proteins & Microarrays Category Retroviruses Papilloma Orthopoxviruses Herpes Viruses Flaviviruses Alphaviruses Bacteria 35,000 Arrays Printed 25,000 Sera Probed Parasites Human Total # of HIV 1&2 (5 clades) HPV viruses (11 types) 3 types HSV 1&2, VZV, EBV WNV, Dengue, YF, SLE, JE Chikungunya Brucella melitensis Chlamydia trachomatis Chlamydia muridarum Mycobacterium tuberculosis Francisella tularensis Coxiella burnetii Borrelia burgdorferi Burkholderia pseudomallei Leptospira interrogans Salmonella enterica thyphi Orientia tsutsugamushi Rickettsia ricketsii Bartonella henselae Clostridium difficile Staphylococcus aureus (MRSA) Streptococcus pneumoniae Enteric toxogenic E. coli Plasmodium falciparum Plasmodium vivax Schistosoma mansoni Toxoplasma gondii Cytauxzoon felis Necator americanus Trypanosoma cruzi Trypanosoma brucei Autoimmune array Ovarian, Breast & Pancreas Cancer A C B C A B B B C B B Total # proteins # cloned %proteome 100% 83 83 100% 88 88 100% 260 260 100% 300 300 100% 50 50 100% 10 10 100% 3,194 3,190 99% 911 900 99% 911 900 98% 3,990 3,899 97% 1,933 1,874 97% 2,065 2,000 97% 1,600 1,540 24% 5,728 1,400 100% 3,658 3,658 99% 4,318 4,300 100% 1,400 1,400 100% 900 900 100% 1,400 1,400 3,747 100% 3,747 95% 2,628 2,509 100% 2,200 2,200 100% 9,000 9,000 97% 5,643 5,400 60% 5,300 3,200 10% 9,000 900 30% 12,000 4,000 20% 4,300 850 5% 12,000 600 2% 15,099 240 3% 8,529 214 9% 21,000 1,800 " " 62,812 $>18 MM STTR/SBIR Awards STTR 1. Vaccinia Proteome Affinity Reagents From Phage Display (NIH-NIAID, $1 million / 2y) 2. Scanning Chlamydia Proteome for Vaccine Antigens (NICHD-NIAID, $600K / 2y) 3. Scanning Chlamydia Proteome for Vaccine Antigens (NICHD-NIAID, $1.8 million/ 2y) SBIR 1. Phage Display for antigen discovery (NIH-NIAID, $1 million / 2yr) 2. Scanning the P. falciparum Proteome for Vaccine Antigens (NIH-NIAID, $600K / 2y) 3. Adjuvants for Agile Vaccine Development (NIH-NIAID, $1 million / 2y) 4. Multiplex Serodiagnostic Test for Lyme Disease (NIH-NIAID, $534K / 1y) 5. Antibody profiles in single and mixed-species malaria infections (NIH-NIAID, $600K / 2y) 6. Serodiagnostics Chips for Biodefense and Emerging Inf. Dis. (NIAID-NCRR, $3Million/3y) 7. Protective Biomarkers for the development of vaccines against malaria (NIAID, $2.3 Million/3y) What are the tools of successful Entrepreneurship? (Wollaeger) Technology Sustaining vs. Disruptive Patents – a vocation, not inspiration don’t have to appear out of the blue Scientists and engineers can learn to invent Capitol Grants – SBIR/STTR Contracts – NIH, Industry Angels – ~$1M; 10X return in 10 yrs Venture – ~$10M; 5X return in 5 yrs People Teamwork Difference in Orientation & Scope Between R01 and SBIR Grants R01 Grant Understand and Communicate Something That Other People Can Learn Small Business (SBIR) Grant Make Something That Other People Can Use SBIR Advanced Technology Grants The SBIR Funding Opportunity http://grants1.nih.gov/grants/funding/sbir.htm Standard Funding Distribution Phase I - $100,000 for 6 months Proof of Concept Phase II - $750,000 for 2 years Commercial/Preclinical Development Advanced Technology SBIR/STTR Grants The SBIR Funding Opportunity (Expired Jan 8, 2014) http://grants2.nih.gov/grants/guide/notice-files/NOT-AI-03-049.html Vaccine and Diagnostic Discovery and Development Phase I - $600,000 for 2 years Phase II - $3,000,000 for 3 years Replaced with: Direct Phase II SBIR Grants to Support Biomedical Technology Development New SBIR Funding Opportunity Must use a Small Business with prior SBIR experience Vaccine and Diagnostic Discovery and Development Phase I - $600,000 for 2 years Phase II - $3,000,000 for 3 years Requirments to Qualify for SBIR/STTR Funding Small business <500 people <50% Venture Capital Equity Support SBIR: PI retains >50% employment in the small business 60% $$ to small business / 40% $$ to UCI STTR: PI can be 100% with UCI 60% $$ to UCI / 40% $$ to small business Accessing Small Business Grants & Contracts at UCI Commercial Distribution & Licensing Agreements New Products & Services UCI Lab Technology, Staff & Resources Research and Development Supported by Small Grants (SBIR & STTR) and by Government and Commercial Contracts An Active Example: Davies/Guan/ImmPORT SBIR Adjuvants for improved vaccines Commercial Distribution Contracts & Licensing $550,000 / 2 yr New Products & Services $450,000 / 2 yr UCI Novel chemistry Animal studies Does & Don’ts • Talk with the Office of Technology Alliances • File a provisional patent application • Start a small business – Come up with a name and an aim • Apply for SBIR grants – Partner with an established small business • Disclose everything on your Conflict of Interest Forms – Don’t try to keep secrets from the COI committee Synthetic Gene Delivery Systems Discovery of Lipofection: A highly efficient, lipid-mediated DNAtransfection procedure. (Felgner et al. PNAS 1987) Nonviral Strategies for Gene Therapy. (Felgner, Scientific American, 1997) Synthetic Gene Delivery Systems Discovery of Lipofection: A highly efficient, lipid-mediated DNAtransfection procedure. (Felgner et al. PNAS 1987) Nonviral Strategies for Gene Therapy. (Felgner, Scientific American, 1997) From Invention to Innovation Lipofectin & Lipofectamne 2013 2005 1991-2000 1988 1987 1985 • Discovery • Draft Patent application • Publish in PNAS • Patent issued • BRL license • Start Vical Invitrogen $250 Million Annual Sales of Lipofectin & Lipofectamine Invitrogen is supporting 2,000 families with income on sales of these reagents • Life Tech. buys BRL • In vitrogen buys Life Tech. • Patent expires Naked DNA Gene Delivery (Wolff et al. Science 1990) Influenza Naked DNA Vaccine Protection against influenza by injection of DNA encoding a viral protein (Ulmer et. al. Science 1993) 100 % Survival 80 60 40 Control Treated 20 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Days Post Challenge From Invention to Innovation Vical – The Naked DNA Company 2013 1998 - 2002 1996 1993 1990 - 91 1988 • Discovery • Draft Patent application • Published in Nature • Merck License • Initial Public Offering IPO • $350 million • Patent issued • Move to UCI 200 employees Numerous clinical trials underway